CDC IIS: Programmatic and Technical Contact List Update

Having trouble viewing this email? View it as a Web page. You are subscribed to CDC’s Programmatic and Technical Contact List for State/Territory/City Registry Staff email subscription service. This message serves to inform you that the contact information for Arizona has recently been updated and is now available. The CDC has reached over 1.4 million subscribers. Thank you for your support. Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support.

Advertisements

Updates to ACIP General Best Practice Guidelines

Having trouble viewing this email? View it as a Web page. You are subscribed to CDC’s ACIP Vaccine Recommendations email subscription service. The following changes were made to the ACIP Best Practice Guidelines for Immunization in July 2017 Table 3-1. (Recommended and minimum ages and intervals between vaccine doses) Footnote f has been clarified: It now reads, “The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3. This is a special grace period of 2 months which can be used if evaluating records retrospectively. An additional 4 days cannot be added to this grace period prospectively, but can be added retrospectively.” This change is to accommodate a recent subject-matter expert email that allows double dipping of the grace period (adding 4 days to the 2 months) for retrospective validation of series WHOSE 4th DOSE WAS ADMINISTERED AT 12 months of age. This double dipping cannot be applied prospectively, meaning we will only allow a 4 day grace period added to a prospective 6 month interval, and we will only allow a four month interval prospectively (not four months plus four days) if the fourth dose would be administered after 12 months of age. CDSi has been updated to accommodate this. TABLE 4-1. (Contraindications and precautions to commonly used vaccines) Added to LAIV contraindications: “LAIV4 should not be administered to persons who have taken influenza antivirals medications within the previous 48 hours.” This addition is to harmonize this table with the 2017-18 adult schedule. Serogroup B meningococcal vaccine has been added to the table. Added to MMR and Varicella contraindications: “Family history of altered immunocompetence.” To harmonize with the vaccine-specific statements in accommodating infants and toddlers with occult heritable congenital immunodeficiencies. Added to Varicella and Zoster precautions: “Receipt of specific antiviral drugs (acyclovir, famiciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination).” The CDC has reached over 1.4 million subscribers. Thank you for your support. Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support.

CDC News: Immunization MMWRs Update

Having trouble viewing this email? View it as a Web page. You are subscribed to CDC News: Immunization-related MMWRs email subscription service. This message serves to inform you that one or more MMWRs have recently been added to the MMWR page and are now available. The CDC has reached over 1.4 million subscribers. Thank you for your support. Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support.

Register now – Aging & the Immune System: Rethinking Vaccines for Older Adults

Having trouble viewing this email? View it as a Web page. You are subscribed to CDC’s Immunization-related Netconferences email subscription service. The immune system changes with age—making it more difficult for older adults to fight off infections and reducing their response to vaccines. New research on how the immune system changes is already improving the effectiveness of vaccines for older adults and making progress toward ensuring longer, healthier lives for all Americans. Tuesday, Sept. 26 from 12pm-1pm ET, join the National Vaccine Program Office (NVPO) and Centers for Disease Control and Prevention (CDC) for the webinar, Aging & the Immune System: Rethinking Vaccines for Older Adults. Register now The CDC has reached over 1.4 million subscribers. Thank you for your support. Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support.

What’s New at CBER Update

Having trouble viewing this email? View it as a Web page.

What’s New at CBER

You are subscribed to What’s New at CBER for the U.S. Food & Drug Administration (FDA).

This page has been updated recently.

• August 31, 2017 Clinical Review – Afluria Quadrivalent (PDF – 965KB)
  Posted: 9/11/2017
• August 31, 2017 Statistical Review – Afluria Quadrivalent (PDF – 351KB)
  Posted: 9/11/2017

What’s New at CBER Update

Having trouble viewing this email? View it as a Web page.

What’s New at CBER

You are subscribed to What’s New at CBER for the U.S. Food & Drug Administration (FDA).

This page has been updated recently.

• August 29, 2017 Summary Basis for Regulatory Action – Afluria Quadrivalent (PDF – 142KB)
  Posted:9/7/2017
• Influenza Virus Vaccine for the 2017-2018 Season
  Updated: 9/7/2017

What’s New at CBER Update

Having trouble viewing this email? View it as a Web page.

What’s New at CBER

You are subscribed to What’s New at CBER for the U.S. Food & Drug Administration (FDA).

This page has been updated recently.

• Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271; Guidance for Industry (PDF – 171KB)
  Posted: 9/6/2017
• Statistical Review – T.R.U.E. TEST (PDF – 527KB)
  Posted: 9/6/2017
• Clinical Review – T.R.U.E. TEST (PDF – 435KB)
  Posted: 9/6/2017
• New Recommendations to Increase the Dose of GamaSTAN S/D (Immune Globulin [Human]) When Used for Prophylaxis for Hepatitis A
  Posted: 9/6/2017